10-Hydroxycamptothecin

CAS No. 19685-09-7

10-Hydroxycamptothecin ( ChEMBL 273862; NSC 107124 )

Catalog No. M13084 CAS No. 19685-09-7

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 40 In Stock
50MG 54 In Stock
100MG 76 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    10-Hydroxycamptothecin
  • Note
    Research use only, not for human use.
  • Brief Description
    (S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.
  • Description
    (S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.
  • Synonyms
    ChEMBL 273862; NSC 107124
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Topoisomerase
  • Recptor
    Topo I
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    19685-09-7
  • Formula Weight
    364.36
  • Molecular Formula
    C20H16N2O5
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 8 mg/mL warmed (21.95 mM)
  • SMILES
    O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O
  • Chemical Name
    (S)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Teicher BA. Biochem Pharmacol. 2007 Oct 22;.
molnova catalog
related products
  • Topovale

    Topovale is a potent inhibitor of topoisomerase I. Topovale inhibits hypoxia-mediated accumulation of hypoxia-inducible factor-1alpha.

  • Idarubicin

    Idarubicin (4-Demethoxydaunorubicin;IMI-30;NSC 256439) is an anthracycline antileukemic that inserts into DNA and prevents DNA unwinding by interfering with the enzyme Topoisomerase II in cancer cells.

  • GW842166X

    GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.